ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

The European Society for Medical Oncology (ESMO) held a virtual consensus-building process on epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer in 2021. The consensus included a multidisciplinary panel of 34 leading experts in the management of lung cancer. The aim of the con...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology Jg. 33; H. 5; S. 466
Hauptverfasser:	Passaro, A, Leighl, N, Blackhall, F, Popat, S, Kerr, K, Ahn, M J, Arcila, M E, Arrieta, O, Planchard, D, de Marinis, F, Dingemans, A M, Dziadziuszko, R, Faivre-Finn, C, Feldman, J, Felip, E, Curigliano, G, Herbst, R, Jänne, P A, John, T, Mitsudomi, T, Mok, T, Normanno, N, Paz-Ares, L, Ramalingam, S, Sequist, L, Vansteenkiste, J, Wistuba, I I, Wolf, J, Wu, Y L, Yang, S R, Yang, J C H, Yatabe, Y, Pentheroudakis, G, Peters, S
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England 01.05.2022
Schlagworte:	Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Consensus ErbB Receptors - genetics Humans Lung Neoplasms - genetics Lung Neoplasms - therapy Medical Oncology consensus lung cancer targeted therapy treatment EGFR testing
ISSN:	1569-8041, 1569-8041
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	The European Society for Medical Oncology (ESMO) held a virtual consensus-building process on epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer in 2021. The consensus included a multidisciplinary panel of 34 leading experts in the management of lung cancer. The aim of the consensus was to develop recommendations on topics that are not covered in detail in the current ESMO Clinical Practice Guideline and where the available evidence is either limited or conflicting. The main topics identified for discussion were: (i) tissue and biomarkers analyses; (ii) early and locally advanced disease; (iii) metastatic disease and (iv) clinical trial design, patient's perspective and miscellaneous. The expert panel was divided into four working groups to address questions relating to one of the four topics outlined above. Relevant scientific literature was reviewed in advance. Recommendations were developed by the working groups and then presented to the entire panel for further discussion and amendment before voting. This manuscript presents the recommendations developed, including findings from the expert panel discussions, consensus recommendations and a summary of evidence supporting each recommendation.
AbstractList	The European Society for Medical Oncology (ESMO) held a virtual consensus-building process on epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer in 2021. The consensus included a multidisciplinary panel of 34 leading experts in the management of lung cancer. The aim of the consensus was to develop recommendations on topics that are not covered in detail in the current ESMO Clinical Practice Guideline and where the available evidence is either limited or conflicting. The main topics identified for discussion were: (i) tissue and biomarkers analyses; (ii) early and locally advanced disease; (iii) metastatic disease and (iv) clinical trial design, patient's perspective and miscellaneous. The expert panel was divided into four working groups to address questions relating to one of the four topics outlined above. Relevant scientific literature was reviewed in advance. Recommendations were developed by the working groups and then presented to the entire panel for further discussion and amendment before voting. This manuscript presents the recommendations developed, including findings from the expert panel discussions, consensus recommendations and a summary of evidence supporting each recommendation. The European Society for Medical Oncology (ESMO) held a virtual consensus-building process on epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer in 2021. The consensus included a multidisciplinary panel of 34 leading experts in the management of lung cancer. The aim of the consensus was to develop recommendations on topics that are not covered in detail in the current ESMO Clinical Practice Guideline and where the available evidence is either limited or conflicting. The main topics identified for discussion were: (i) tissue and biomarkers analyses; (ii) early and locally advanced disease; (iii) metastatic disease and (iv) clinical trial design, patient's perspective and miscellaneous. The expert panel was divided into four working groups to address questions relating to one of the four topics outlined above. Relevant scientific literature was reviewed in advance. Recommendations were developed by the working groups and then presented to the entire panel for further discussion and amendment before voting. This manuscript presents the recommendations developed, including findings from the expert panel discussions, consensus recommendations and a summary of evidence supporting each recommendation.The European Society for Medical Oncology (ESMO) held a virtual consensus-building process on epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer in 2021. The consensus included a multidisciplinary panel of 34 leading experts in the management of lung cancer. The aim of the consensus was to develop recommendations on topics that are not covered in detail in the current ESMO Clinical Practice Guideline and where the available evidence is either limited or conflicting. The main topics identified for discussion were: (i) tissue and biomarkers analyses; (ii) early and locally advanced disease; (iii) metastatic disease and (iv) clinical trial design, patient's perspective and miscellaneous. The expert panel was divided into four working groups to address questions relating to one of the four topics outlined above. Relevant scientific literature was reviewed in advance. Recommendations were developed by the working groups and then presented to the entire panel for further discussion and amendment before voting. This manuscript presents the recommendations developed, including findings from the expert panel discussions, consensus recommendations and a summary of evidence supporting each recommendation.
Author	Sequist, L Normanno, N Curigliano, G Yatabe, Y Faivre-Finn, C Yang, J C H Paz-Ares, L Mitsudomi, T Dingemans, A M Herbst, R Felip, E Passaro, A Ramalingam, S Blackhall, F Yang, S R Peters, S Kerr, K Planchard, D Feldman, J de Marinis, F Jänne, P A Mok, T Popat, S Wistuba, I I Arcila, M E Dziadziuszko, R Arrieta, O Wolf, J Pentheroudakis, G Wu, Y L John, T Ahn, M J Leighl, N Vansteenkiste, J
Author_xml	– sequence: 1 givenname: A surname: Passaro fullname: Passaro, A email: antonio.passaro@ieo.it organization: Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy. Electronic address: antonio.passaro@ieo.it – sequence: 2 givenname: N surname: Leighl fullname: Leighl, N organization: Division of Medical Oncology/Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Canada – sequence: 3 givenname: F surname: Blackhall fullname: Blackhall, F organization: Division of Cancer Sciences, The University of Manchester, Manchester, UK; Department of Medical Oncology, The Christie National Health Service (NHS) Foundation Trust, Manchester, UK – sequence: 4 givenname: S surname: Popat fullname: Popat, S organization: National Heart and Lung Institute, Imperial College, London, UK; Lung Unit, Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK – sequence: 5 givenname: K surname: Kerr fullname: Kerr, K organization: Aberdeen Royal Infirmary, Aberdeen University Medical School, Aberdeen, UK – sequence: 6 givenname: M J surname: Ahn fullname: Ahn, M J organization: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea – sequence: 7 givenname: M E surname: Arcila fullname: Arcila, M E organization: Department of Pathology, Molecular Diagnostics Service, Memorial Sloan Kettering Cancer Center, New York, USA – sequence: 8 givenname: O surname: Arrieta fullname: Arrieta, O organization: Thoracic Oncology Unit, Instituto Nacional de Cancerología, Mexico City, Mexico – sequence: 9 givenname: D surname: Planchard fullname: Planchard, D organization: Department of Medical Oncology, Gustave Roussy, Villejuif, France – sequence: 10 givenname: F surname: de Marinis fullname: de Marinis, F organization: Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy – sequence: 11 givenname: A M surname: Dingemans fullname: Dingemans, A M organization: Department of Respiratory Medicine, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands – sequence: 12 givenname: R surname: Dziadziuszko fullname: Dziadziuszko, R organization: Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdansk, Poland – sequence: 13 givenname: C surname: Faivre-Finn fullname: Faivre-Finn, C organization: The University of Manchester, Manchester Academic Health Science Centre, The Christie NHS Foundation Trust, Manchester, UK – sequence: 14 givenname: J surname: Feldman fullname: Feldman, J organization: Lung Cancer Patient and Advocate, Co-Founder of EGFR Resisters Patient Group – sequence: 15 givenname: E surname: Felip fullname: Felip, E organization: Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain – sequence: 16 givenname: G surname: Curigliano fullname: Curigliano, G organization: Department of Oncology and Hemato-Oncology, University of Milano, European Institute of Oncology IRCCS, Milan, Italy – sequence: 17 givenname: R surname: Herbst fullname: Herbst, R organization: Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, USA – sequence: 18 givenname: P A surname: Jänne fullname: Jänne, P A organization: Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA – sequence: 19 givenname: T surname: John fullname: John, T organization: Peter MacCallum Cancer Centre, Melbourne, Australia – sequence: 20 givenname: T surname: Mitsudomi fullname: Mitsudomi, T organization: Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan – sequence: 21 givenname: T surname: Mok fullname: Mok, T organization: State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, Hong Kong, China – sequence: 22 givenname: N surname: Normanno fullname: Normanno, N organization: Cell Biology and Biotherapy and Scientific Directorate, Istituto Nazionale Tumori, "Fondazione G.Pascale" IRCCS, Naples, Italy – sequence: 23 givenname: L surname: Paz-Ares fullname: Paz-Ares, L organization: Lung Cancer Clinical Research Unit, and Complutense University, Madrid, Spain – sequence: 24 givenname: S surname: Ramalingam fullname: Ramalingam, S organization: Department of Hematology and Medical Oncology, Winship Cancer Institute, Atlanta, Georgia – sequence: 25 givenname: L surname: Sequist fullname: Sequist, L organization: Department of Medicine, Massachusetts General Hospital, Boston, USA – sequence: 26 givenname: J surname: Vansteenkiste fullname: Vansteenkiste, J organization: Department of Respiratory Oncology, University Hospital KU Leuven, Leuven, Belgium – sequence: 27 givenname: I I surname: Wistuba fullname: Wistuba, I I organization: Department of Translational Molecular Pathology, Unit 951, The University of Texas MD Anderson Cancer Center, Houston, USA – sequence: 28 givenname: J surname: Wolf fullname: Wolf, J organization: Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany – sequence: 29 givenname: Y L surname: Wu fullname: Wu, Y L organization: Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangdong, China – sequence: 30 givenname: S R surname: Yang fullname: Yang, S R organization: The Institute of Cancer Research, London, UK – sequence: 31 givenname: J C H surname: Yang fullname: Yang, J C H organization: Department of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Republic of China – sequence: 32 givenname: Y surname: Yatabe fullname: Yatabe, Y organization: Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan – sequence: 33 givenname: G surname: Pentheroudakis fullname: Pentheroudakis, G organization: Department of Medical Oncology, University of Ioannina, Ioannina, Epirus, Greece – sequence: 34 givenname: S surname: Peters fullname: Peters, S organization: Oncology Department - CHUV, Lausanne University, Lausanne, Switzerland
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/35176458$$D View this record in MEDLINE/PubMed
BookMark	eNpNkFtLw0AQhRep2Iv-A5F99CVxb9kkj1LaKlQK2kchzG4mtSXZ1OwG9N8btYIwcOZ8HIbDTMnItQ4JueYs5ozru0MMbkA2FkyImA3D5BmZ8ETnUcYUH_3bx2Tq_YExpnORX5CxTHiqVZJNyOvi5WlD8eOIXaC2dR6d7z31AQI26IKnraPhDWkDDnY_iLYVXayWz7TpAwx2KBH5Buo6sljXtO7djlpwFrtLcl5B7fHqpDOyXS6284dovVk9zu_XkVWpClGZVpXiUoKyOjO8TA0iKiy5EkZLbjAzOSQ5AAiWGpNkKFJmQSZ5xirGxYzc_p49du17jz4Uzd5_dwGHbe8LoSXLJZeJHqI3p2hvGiyLY7dvoPss_h4ivgDZVmak
CitedBy_id	crossref_primary_10_1016_j_tranon_2024_102022 crossref_primary_10_1080_14737159_2024_2303320 crossref_primary_10_1016_j_esmoop_2025_105807 crossref_primary_10_1016_j_hoc_2023_02_007 crossref_primary_10_1002_cam4_6184 crossref_primary_10_1016_j_lungcan_2022_11_002 crossref_primary_10_1055_a_2359_2150 crossref_primary_10_1016_j_annonc_2023_10_117 crossref_primary_10_1016_j_annonc_2022_06_013 crossref_primary_10_3390_cancers16142589 crossref_primary_10_3390_ijms23136936 crossref_primary_10_1111_1759_7714_15317 crossref_primary_10_1038_s41392_024_01982_2 crossref_primary_10_1177_10781552231224372 crossref_primary_10_1016_j_jtho_2023_06_012 crossref_primary_10_1002_cam4_7208 crossref_primary_10_1007_s12094_025_04015_8 crossref_primary_10_1016_j_jtho_2024_04_006 crossref_primary_10_1016_j_cllc_2024_08_014 crossref_primary_10_1016_j_lungcan_2024_108076 crossref_primary_10_1200_EDBK_432516 crossref_primary_10_3390_cancers17050847 crossref_primary_10_1177_10732748251342685 crossref_primary_10_1007_s00262_023_03370_1 crossref_primary_10_1080_14656566_2025_2464903 crossref_primary_10_1080_14712598_2025_2507833 crossref_primary_10_1007_s12094_025_03971_5 crossref_primary_10_1111_1759_7714_14635 crossref_primary_10_1136_jitc_2024_010500 crossref_primary_10_1002_cncr_35112 crossref_primary_10_3390_cancers15030841 crossref_primary_10_1016_j_ctrv_2024_102824 crossref_primary_10_1177_17588359241234504 crossref_primary_10_1038_s41416_024_02709_4 crossref_primary_10_1038_s41392_025_02358_w crossref_primary_10_1016_j_jtocrr_2022_100401 crossref_primary_10_1200_EDBK_432488 crossref_primary_10_7554_eLife_99341_3 crossref_primary_10_1002_cam4_6886 crossref_primary_10_1016_j_critrevonc_2022_103760 crossref_primary_10_1016_j_lungcan_2025_108100 crossref_primary_10_1016_j_critrevonc_2023_104010 crossref_primary_10_1007_s40487_023_00242_7 crossref_primary_10_1016_j_lungcan_2025_108748 crossref_primary_10_1016_j_medj_2024_09_002 crossref_primary_10_3390_ijms23084164 crossref_primary_10_1016_j_lungcan_2022_05_007 crossref_primary_10_1183_16000617_0200_2023 crossref_primary_10_2147_OTT_S513879 crossref_primary_10_1016_j_crad_2024_01_005 crossref_primary_10_1186_s12964_023_01139_8 crossref_primary_10_1016_j_esmorw_2025_100152 crossref_primary_10_3390_biomedicines13040814 crossref_primary_10_1016_j_annonc_2022_12_009 crossref_primary_10_1016_j_clon_2022_08_025 crossref_primary_10_1002_med4_44 crossref_primary_10_1016_j_crad_2024_04_019 crossref_primary_10_3390_ijms24108878 crossref_primary_10_7554_eLife_99341 crossref_primary_10_1177_17588359221113268 crossref_primary_10_1016_j_ejca_2023_02_013 crossref_primary_10_1016_j_jtho_2025_05_004 crossref_primary_10_1186_s12885_024_12826_1 crossref_primary_10_1016_j_xgen_2025_100987 crossref_primary_10_1016_j_ctrv_2023_102602 crossref_primary_10_1136_jcp_2024_209941 crossref_primary_10_7759_cureus_33577 crossref_primary_10_1056_NEJMe2406495 crossref_primary_10_1016_j_tranon_2023_101772 crossref_primary_10_1016_j_jtocrr_2024_100669 crossref_primary_10_1007_s10637_025_01505_y crossref_primary_10_1016_j_jtocrr_2022_100388 crossref_primary_10_1016_j_lungcan_2025_108447 crossref_primary_10_1007_s13577_023_00980_w crossref_primary_10_1038_s41598_023_45337_3 crossref_primary_10_1515_almed_2025_0012 crossref_primary_10_1016_j_cllc_2025_05_012 crossref_primary_10_1097_MD_0000000000034483 crossref_primary_10_1186_s13045_024_01656_0 crossref_primary_10_1515_almed_2025_0092 crossref_primary_10_3390_ijms26072957 crossref_primary_10_1111_ajco_14147 crossref_primary_10_3389_fonc_2023_1108124 crossref_primary_10_3389_fonc_2023_1330468 crossref_primary_10_1007_s00432_024_05828_w crossref_primary_10_1016_j_lungcan_2025_108452 crossref_primary_10_1016_j_critrevonc_2024_104483 crossref_primary_10_1016_j_lungcan_2025_108699 crossref_primary_10_3390_cancers17091515 crossref_primary_10_1016_j_ijrobp_2023_11_005 crossref_primary_10_1080_17476348_2023_2265810 crossref_primary_10_1016_j_jvir_2024_10_008 crossref_primary_10_3389_fonc_2022_1024655 crossref_primary_10_1186_s42047_023_00138_w crossref_primary_10_1007_s11030_024_11067_5 crossref_primary_10_62347_WTMU5537 crossref_primary_10_3390_healthcare10091714 crossref_primary_10_1016_j_mpdhp_2024_04_003 crossref_primary_10_1007_s12254_024_00960_2 crossref_primary_10_3233_CBM_230124 crossref_primary_10_1016_j_lungcan_2023_107414 crossref_primary_10_1016_j_lungcan_2025_108549 crossref_primary_10_3390_jpm14050446 crossref_primary_10_1016_j_annonc_2025_08_003 crossref_primary_10_1186_s12885_022_09444_0 crossref_primary_10_1002_cam4_70827 crossref_primary_10_1038_s41598_024_63821_2 crossref_primary_10_3389_fsurg_2022_1038219 crossref_primary_10_1093_oncolo_oyae312 crossref_primary_10_1016_j_jtocrr_2024_100774 crossref_primary_10_1016_j_canlet_2024_216930 crossref_primary_10_3389_pore_2024_1611716 crossref_primary_10_1016_j_lungcan_2025_108716 crossref_primary_10_1177_17588359231193726 crossref_primary_10_1186_s13148_025_01899_9 crossref_primary_10_1016_j_rmr_2024_05_003 crossref_primary_10_3390_cancers15092648 crossref_primary_10_1016_j_ctrv_2023_102671 crossref_primary_10_1016_j_lungcan_2022_08_004 crossref_primary_10_1111_ajco_13875 crossref_primary_10_7326_ANNALS_25_00963 crossref_primary_10_1089_ars_2024_0808
ContentType	Journal Article
Copyright	Copyright © 2022 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.
Copyright_xml	– notice: Copyright © 2022 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1016/j.annonc.2022.02.003
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1569-8041
ExternalDocumentID	35176458
Genre	Journal Article
GroupedDBID	--- -E4 .2P .86 .I3 .XZ .ZR 08P 0R~ 0U7 1TH 23M 2WC 4.4 482 48X 53G 5GY 5VS 5WA 6.Y 6J9 70D AAEDW AAGQS AAJKP AAJQQ AAKAS AAKUH AALRI AAMVS AAOGV AAPNW AAUQX AAXUO ABEUO ABIXL ABJNI ABKDP ABLJU ABNGD ABNKS ABOCM ABQLI ABQTQ ABSAR ABSMQ ABZBJ ACGFO ACGFS ACPQN ACPRK ACUFI ACUTO ADBBV ADEYI ADHKW ADHZD ADJQC ADOCK ADRIX ADRTK ADVLN ADYVW ADZCM ADZXQ AEGPL AEGXH AEHUL AEJOX AEKPW AEKSI AEMDU AENEX AENZO AEPUE AEWNT AFETI AFIYH AFJKZ AFOFC AFSHK AFXEN AGINJ AGKEF AGKRT AGSYK AHMBA AHXPO AIAGR AIJHB AITUG AKRWK ALMA_UNASSIGNED_HOLDINGS ALUQC AMRAJ APIBT APWMN AQKUS ASPBG ATTQO AVWKF AXUDD AZFZN BAWUL BAYMD BGNMA BHONS BTRTY BVRKM BZKNY C1A CAG CDBKE CGR CKLRP COF CS3 CUY CVF CZ4 DAKXR DIK DILTD DL5 D~K E3Z EBS ECM EE~ EIF EJD EX3 F9B FDB FEDTE GJXCC GX1 H13 H5~ HAR HVGLF HW0 HZ~ I09 IH2 IHE IOX J21 KAQDR KDC KOM KOP KQ8 KSI KSN LAK M-Z M41 M49 M4Y MBLQV MHKGH N9A NCXOZ NGC NOYVH NPM NTWIH NU0 NVLIB O9- OAWHX ODMLO OJQWA OK1 OVD P2P P6G PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD R44 RD5 RNI ROL ROX ROZ RPX RW1 RXO RZC RZE RZF RZO SDH TCURE TEORI TJX TMA TR2 U2A W8F WOQ WOW X7H YAYTL YFH YKOAZ ZKX ZXP ~91 7X8 ACVFH ADCNI AEUPX AFPUW AIGII AKBMS AKYEP APXCP EFKBS
ID	FETCH-LOGICAL-c474t-d7ff4133a4c68b1d7beee4ed142b631be8b9a59aaa207bb58e270ca35980f012
IEDL.DBID	7X8
ISICitedReferencesCount	136
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000797900700004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1569-8041
IngestDate	Sun Sep 28 10:56:26 EDT 2025 Wed Feb 19 02:25:54 EST 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	5
Keywords	consensus lung cancer targeted therapy treatment EGFR testing
Language	English
License	Copyright © 2022 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c474t-d7ff4133a4c68b1d7beee4ed142b631be8b9a59aaa207bb58e270ca35980f012
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Instructional Material/Guideline-3 content type line 23
OpenAccessLink	http://www.annalsofoncology.org/article/S0923753422001120/pdf
PMID	35176458
PQID	2630931356
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_2630931356 pubmed_primary_35176458
PublicationCentury	2000
PublicationDate	2022-05-00 20220501
PublicationDateYYYYMMDD	2022-05-01
PublicationDate_xml	– month: 05 year: 2022 text: 2022-05-00
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	Annals of oncology
PublicationTitleAlternate	Ann Oncol
PublicationYear	2022
SSID	ssj0006929
Score	2.6753497
Snippet	The European Society for Medical Oncology (ESMO) held a virtual consensus-building process on epidermal growth factor receptor (EGFR)-mutant non-small-cell...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	466
SubjectTerms	Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Consensus ErbB Receptors - genetics Humans Lung Neoplasms - genetics Lung Neoplasms - therapy Medical Oncology
Title	ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
URI	https://www.ncbi.nlm.nih.gov/pubmed/35176458 https://www.proquest.com/docview/2630931356
Volume	33
WOSCitedRecordID	wos000797900700004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_agvVvC6mGTfJxFp9WBr0R56EMLuZgNCm9Sm9fe7u0ntSRC85BJCNjOTmdmdb74B4IaJTJFMKKSp0IgYjJHMiLPlLFJU0TyxODQKP_N-X4xGctAcuFUNrHLpE4Ojzkrjz8hvE-ZrdjGm7G76ifzUKF9dbUZorIOWuyU9pIuPVmzhTIYpZW6LIpHn2Vm2zgV8lyrc_tqTGCZJzdqJf08yQ7Dp7v53mXtgp0kz4X1tF_tgzRYHYKvXFNIPwXvnrfcCA73_HBqPqC6qRQVDe1FoeoNlAV1uCCc_8BhY5rDz2H2Fk4WfPAzdd6FqosZj5A__4dh5DWi8Dc2OwLDbGT48oWbQAjKEkznKeJ67YIYVMUzoOOPaWktsFpNEMxxrK7RUVCqlkohrp1Wb8MgoT_4X5S7CHYMN9057CqBPWLwmXOSVRCsquIqUZrm2Lg1hVrfB9VJsqbNjvz5V2HJRpSvBtcFJLft0WhNupJjGnBEqzv7w9DnY9iqtMYkXoJW7v9hegk3zNf-oZlfBQNy1P-h9A2eIxiw
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=ESMO+expert+consensus+statements+on+the+management+of+EGFR+mutant+non-small-cell+lung+cancer&rft.jtitle=Annals+of+oncology&rft.au=Passaro%2C+A&rft.au=Leighl%2C+N&rft.au=Blackhall%2C+F&rft.au=Popat%2C+S&rft.date=2022-05-01&rft.eissn=1569-8041&rft.volume=33&rft.issue=5&rft.spage=466&rft_id=info:doi/10.1016%2Fj.annonc.2022.02.003&rft_id=info%3Apmid%2F35176458&rft_id=info%3Apmid%2F35176458&rft.externalDocID=35176458
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1569-8041&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1569-8041&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1569-8041&client=summon